CASRAI Dictionary

Tag: nih grant restoration

  • NIH Grant Termination Study: What the Data Show

    Independent tracking studies of the National Institutes of Health’s 2025 grant terminations show the cuts did not fall evenly across the biomedical research portfolio. This NIH grant termination study review of four separate tracking efforts finds early-career investigators, women-led projects, infectious-disease and health-equity research, and a small cluster of NIH institutes and institutions absorbed a disproportionate share of the losses.

    An NIH grant termination study, in this context, is an independent, data-driven analysis — built from crowd-sourced trackers such as Grant Witness and NIH’s own Research Portfolio Online Reporting Tools (RePORTER) — that quantifies which grants the agency cancelled and who held them, because NIH has not published a single consolidated breakdown of its own.

    How independent studies measured the terminations

    NIH has not released an official, comprehensive tally of terminated awards, so researchers and journalists have relied on independent trackers to reconstruct the picture. Four efforts now anchor most public analysis:

    • Fregolent et al. (2026), published in PNAS, matched the crowd-sourced Grant Witness database against NIH RePORTER records for grants cancelled between February and August 2025.
    • Patel, Liu and Jena (2025), published in JAMA Internal Medicine, linked NIH ExPORTER data with the HHS Tracking Accountability in Government Grants System for a narrower 28 February–8 April 2025 window.
    • The Association of American Medical Colleges (AAMC) published a running snapshot of terminations as of 5 May 2025.
    • A PubMed Central review (Faiman et al., 2025) tracked cumulative losses across the calendar year, including clinical-trial detail by disease area.

    Because each study samples a different date range and data source, the headline totals diverge — but the pattern of who was affected is remarkably consistent across all four.

    Which career stages absorbed the deepest cuts

    Training and early-career funding took a disproportionate hit. Under the PNAS analysis, women held 60% of the 530 cancelled grants among assistant professors and doctoral students, while men lost 59% of the 1,410 cancelled grants held by professors and associate professors — meaning losses skewed toward more junior investigators even as senior researchers lost more total dollars.

    Predoctoral and undergraduate pipeline awards were hit hardest of all: women held 58% of cancelled F31 and F30 predoctoral fellowships and 66% of cancelled T34 undergraduate research awards. NIH terminated $56.8 million across these early-career programmes and a further $329.6 million in T32 institutional training grants. Separately, the AAMC tracker found 29% of all terminated grants were research training or career-development awards, versus 61% classified as standard research-and-development grants — a training-pipeline share roughly double what its overall funding weight would predict.

    Which fields and institutes were hit hardest

    By institute, the National Institute of Mental Health recorded the highest number of terminations (128 grants), followed by the National Institute on Minority Health and Health Disparities (77 grants), according to the JAMA Internal Medicine analysis. By dollar value, the National Institute of Allergy and Infectious Diseases lost the most funding ($505.9 million), with NIMHD second ($223.6 million).

    Clinical-trial data tell a parallel story: infectious-disease trials were the most affected topic area, at 14.4% of active trials disrupted, compared with 2.2% for neurologic and reproductive-health trials. Prevention-focused trials lost funding at more than four times the rate of basic-science trials (8.4% versus 2.0%). A separate PubMed Central review tallied at least 160 disrupted clinical trials spanning cancer and HIV/AIDS research, within a cumulative $3.8 billion in terminated NIH funding tracked across 2025.

    Which institutions and regions felt the impact

    Terminations touched 210 recipient institutions, but concentration was high: Columbia University recorded the most terminations of any single institution (157 grants) in the JAMA Internal Medicine sample. Geographically, trials based in the Northeast US were terminated at 6.3%, the highest of any US region, while multiregional US trials saw none. International trials lost funding at a higher rate than domestic ones (5.8% versus 3.4%), suggesting non-US collaborators carried a heavier share of the disruption than US-only projects.

    How the four tracking studies compare

    Reading the totals side by side clarifies why headline figures vary so widely in news coverage — each study samples a different window and a different data source, not a different underlying event.

    Study Snapshot window Grants terminated Value tracked Distinct focus
    Fregolent et al., PNAS (2026) Feb–Aug 2025 2,291 terminated; 1,534 frozen $2.45 billion Gender and career-stage breakdown
    Patel et al., JAMA Intern Med (2025) 28 Feb–8 Apr 2025 694 $1.81 billion Clinical-trial disruption by institute, topic, region
    AAMC tracker As of 5 May 2025 777 $1.9 billion Grant-type split (research vs training)
    Faiman et al., PubMed Central (2025) Cumulative, 2025 160+ clinical trials $3.8 billion Disease-area detail (cancer, HIV/AIDS)

    Answer-first Q&A

    Which universities get the most NIH funding?

    Johns Hopkins University has historically led all US institutions in total NIH support, with other top recipients including the University of Washington, Stanford and the University of Michigan. Institutions with large NIH portfolios are not automatically those hit hardest by terminations — Columbia University topped the termination count despite not leading in total funding received.

    How much did the Trump administration cut from the NIH budget?

    The administration’s fiscal year 2026 budget request proposed a roughly 40% reduction to NIH’s overall budget, alongside the direct termination of thousands of active awards earlier in 2025. Congress has not enacted a cut of that scale, and litigation over specific terminations remains ongoing into 2026.

    Who is considered the biggest funder of biomedical research?

    NIH is the largest single public funder of biomedical and behavioural research in the world, with an annual budget exceeding $47 billion. That scale is why even a partial termination round — a few thousand of the roughly 50,000 active awards — produced measurable, trackable disruption across the sector.

    What this means for institutions and funders

    For research administrators, the consistent finding across all four studies is that training and early-career awards carry outsized termination risk relative to their share of total NIH spending. Institutions with concentrated early-career or health-equity portfolios should treat independent trackers such as Grant Witness and NIH RePORTER as live risk-monitoring tools, not just retrospective journalism sources, when advising principal investigators on contingency funding and bridge support.

    The divergence between studies also carries a methodological lesson for anyone citing termination figures: always state the snapshot date and data source alongside any total, since “NIH grant terminations” without a date range can mean anywhere from 694 to over 2,291 awards depending on which tracking effort is cited.

    Outlook: restoration, litigation and ongoing tracking

    Not all terminations have proved final. Litigation challenging terminations tied to diversity, equity and gender-related research topics has led to court-ordered reinstatement of some awards during 2025, and appeals continue into 2026. Independent trackers, including Grant Witness and the Impact Project, are continuing to log both new terminations and restorations, meaning the totals in this piece are a snapshot, not an endpoint.

    Researchers and administrators should expect further peer-reviewed analyses through 2026 as tracking teams extend their datasets — particularly on downstream effects for publications, collaborations and workforce retention, which the PNAS authors flag as their next research target. For institutions building sponsored-research risk frameworks, this body of independent tracking work is now a more reliable source than any single news report of the terminations themselves.

  • NIH Grant Cancellation Legality Under 2 CFR 200

    NIH grant cancellation legality rests on 2 CFR 200.340: a grant may be terminated mid-cycle only if the recipient fails to comply with award terms, both parties consent, or the awarding agency determines the project no longer effectuates programme goals — and in every case NIH must issue written notice and preserve the recipient’s appeal rights before funding stops.

    A grant termination is the enforceable act of ending some or all of an active federal award before its approved project period expires, distinct from the routine non-renewal of a grant at the end of a competitive cycle. Understanding where that line sits — and what procedural protections apply on either side of it — is now a core competency for research administrators, not a hypothetical.

    Federal grant terminations are governed by the OMB Uniform Guidance codified at 2 CFR 200.340, which HHS incorporates into its own grants regulations and which NIH restates in Section 8.5.2 of the NIH Grants Policy Statement (“Suspension, Termination, and Withholding of Support”). This is an administrative-law standard, not a discretionary one: an awarding agency cannot terminate a grant for an unlisted reason, however compelling it finds that reason.

    NIH’s default posture, per its own policy statement, is to suspend a grant and give the recipient an opportunity for corrective action before proceeding to full termination — except where a serious deficiency or risk to health or safety justifies immediate termination.

    What grounds allow NIH to cancel a grant mid-cycle?

    2 CFR 200.340 recognises a closed, not open-ended, list of termination grounds. The Center for Science in the Public Interest’s litigation summary of APHA v. NIH describes these as “three limited circumstances” under the regulation.

    Ground Regulatory basis Typical trigger
    Recipient non-compliance 2 CFR 200.340(a)(1) Failure to meet award terms and conditions, financial mismanagement, or research misconduct findings
    Mutual agreement 2 CFR 200.340(a)(2) Recipient and NIH jointly agree the project is no longer viable (e.g. PI departure)
    Agency priorities / “for cause” 2 CFR 200.340(a)(4) NIH determines the award “no longer effectuates the program goals or agency priorities”

    The third ground is the one currently under judicial scrutiny. It gives the agency real latitude to align funding with shifting priorities, but that latitude is not unlimited: agency reasoning must still satisfy the Administrative Procedure Act’s bar on “arbitrary and capricious” action, meaning NIH must show a reasoned, non-conclusory basis tied to the individual award rather than a blanket, category-wide directive.

    What notice and appeal rights does 2 CFR 200 guarantee?

    Termination is not self-executing. 2 CFR 200.341 requires NIH to provide written notice specifying the reason for termination, the effective date, and whether the termination is full or partial. Where non-compliance is the stated ground, the notice must also disclose that the termination will be reported in the federal System for Award Management (SAM.gov), a public record that can affect an institution’s future funding eligibility.

    Recipients then have a two-tier route to challenge the decision:

    Stage Forum Typical deadline Scope of review
    First-level appeal NIH official named in the termination notice Per notice instructions Procedural and factual objections to the stated grounds
    Formal appeal HHS Departmental Appeals Board 30 days from final NIH decision Whether NIH followed its own regulations and notice requirements

    Disagreement over scientific merit is generally not a valid appeal ground; DAB review focuses on whether NIH complied with its own procedural rules, not on re-litigating peer review.

    How did 2025–26 litigation test these limits?

    The clearest real-world stress test of this framework is American Public Health Association v. NIH (D. Mass., No. 1:25-cv-10787). Beginning in February 2025, NIH terminated a large volume of active grants tied to categories the administration disfavoured, without individualised, award-specific justification.

    On 16 June 2025, District Judge William Young ruled the underlying directives and the resulting terminations arbitrary and capricious under the APA, finding the stated reasons “conclusory and bereft of reasoning.” His 23 June 2025 Partial Final Judgment declared the directives and terminations “of no effect, void, illegal, set aside, and vacated.” The First Circuit unanimously denied the government’s request to stay that judgment on 18 July 2025.

    On 21 August 2025, the Supreme Court issued a narrower, 5–4 emergency-docket ruling: it left the vacatur of the NIH directives in place, but held that district courts likely lack jurisdiction to order restoration of the terminated grants themselves, because such claims sound in contract and belong before the Court of Federal Claims under the Tucker Act. That split — policy directives reviewable in district court, individual grant restoration routed to a separate contract forum — is now the operative jurisdictional map for any institution challenging a termination. As of the case’s most recent public docket update, First Circuit oral argument on the merits appeal was calendared for 6 January 2026, with the outcome not yet reflected in publicly available case summaries at the time of writing.

    Separately, the Government Accountability Office found in August 2025 that NIH’s cancellation of roughly 1,800 grants violated the Impoundment Control Act of 1974, which requires the executive branch to obligate congressionally appropriated funds absent a formal rescission request to Congress. Harvard’s T.H. Chan School of Public Health, tracking the terminations independently, put the broader 2025 total at roughly 2,100 grants worth approximately $9.5 billion.

    Answer-first Q&A: what administrators are asking

    Are NIH grant terminations illegal?

    Not inherently. A termination is lawful when NIH cites one of the three grounds in 2 CFR 200.340, issues proper written notice, and grounds its reasoning in the specific award. A federal court found a 2025 wave of terminations unlawful specifically because NIH skipped individualised justification and relied on blanket, category-based directives instead.

    Can the government cancel a federal grant?

    Yes — federal agencies retain statutory authority to terminate grants “to the extent authorized by law,” including when an award no longer serves programme goals. That authority is bounded by the Administrative Procedure Act, the Impoundment Control Act’s restrictions on withholding appropriated funds, and the agency’s own termination regulations.

    How could researchers get a cancelled NIH grant restored?

    Institutions can pursue NIH’s internal appeal, then the HHS Departmental Appeals Board, or litigate under the APA in district court against the policy directive itself. Per the Supreme Court’s August 2025 ruling, restoration of the underlying funding obligation likely requires a separate contract claim at the Court of Federal Claims.

    How many NIH grants have been cancelled?

    Independent tracking by Harvard’s T.H. Chan School of Public Health documented roughly 2,100 grants worth approximately $9.5 billion terminated during 2025, a volume the litigation record describes as unprecedented against decades in which such terminations were “exceedingly rare.”

    What should research administrators do now?

    Three practical implications follow directly from the legal standard, independent of how any single case resolves:

    • Preserve every termination notice in full — the stated reason under 2 CFR 200.341 determines which appeal forum and deadline apply, and a vague or category-wide reason is itself a procedural defect worth flagging.
    • Track the SAM.gov disclosure trigger — a non-compliance-based termination notice generates a public record that can affect future eligibility, so institutions should confirm the correct ground was cited.
    • Route restoration claims correctly — the 2025 jurisdictional split means a policy challenge and a funds-restoration claim are no longer the same lawsuit, and misfiling in the wrong forum can cost months.

    The underlying legal standard has not changed: NIH still needs one of three grounds, still owes written notice, and recipients still retain a defined appeal path under 2 CFR 200. What 2025–26 litigation changed is the practical burden of proof NIH must meet to invoke the “agency priorities” ground, and the forum in which recipients must seek a remedy. Research administration offices that build both into their grant-monitoring workflow will be far better positioned than those relying on general awareness that “terminations are being challenged in court.”

  • NIH Grant Terminations in 2026: What Was Cancelled, What Was Restored, and Why

    What happened: the 2025-2026 NIH termination wave

    Beginning in March 2025, the National Institutes of Health cancelled thousands of active research awards in one of the largest disruptions to federal biomedical funding in decades. A peer-reviewed analysis published in the Proceedings of the National Academy of Sciences in 2026 counted 2,291 active NIH research grants terminated in the initial wave, withdrawing an estimated $2.45 billion in committed funding. NIH grant terminations continued through the spring, and by late May 2025 Harvard T.H. Chan School of Public Health researchers tracking the cuts put the cumulative total at roughly 2,100 grants worth approximately $9.5 billion.

    Independent counts diverged because institutions and awarding offices reported figures at different points in a fast-moving process. The Association of American Medical Colleges recorded 777 terminated grants representing $1.9 billion as of 5 May 2025, while an implementation-science analysis published in PubMed Central counted 702 terminations as of 5 April 2025. The variance reflects the pace of the cuts rather than disagreement about their occurrence.

    Which grants and research topics were targeted

    Termination notices sent to grantees cited a shift in agency funding priorities away from topics the administration characterised as “unscientific” or as promoting discrimination. Research areas disproportionately affected included:

    • LGBT+ health and gender-identity research
    • Diversity, equity, and inclusion (DEI) initiatives in the biomedical workforce
    • Vaccine hesitancy and confidence studies
    • Health equity and racial health-disparities research
    • Climate change and environmental-health research

    Reporting by Applied Clinical Trials Online found that 20% of terminated grants were early-career training awards, a category central to sustaining the biomedical research pipeline. A subsequent analysis found the cuts fell disproportionately on Black, Indigenous, and other minority researchers, as well as investigators from sexual and gender-minority communities — a pattern that later became central to the legal challenges against the terminations.

    Court-ordered restorations: the timeline

    Multiple lawsuits challenged the terminations as procedurally unlawful and discriminatory. The table below summarises the major rulings tracked through mid-2026.

    Date Ruling / event Outcome
    16 June 2025 Judge William Young (D. Mass.), APHA v. NIH Ordered NIH to restore 367 grants worth nearly $3.8 billion; found the termination process “arbitrary and capricious” and discriminatory toward LGBTQ-related research
    25 June 2025 NIH response to court order NIH ceased issuing new terminations of “politically sensitive” grants while the ruling was contested
    August 2025 Federal court order, UCLA class action Ordered restoration of NSF grants suspended at UCLA from 1 August 2025
    September 2025 Federal court order, UCLA Ordered restoration of NIH funding suspended at UCLA from 31 July 2025; NIH reinstated the awards
    May 2026 Ninth Circuit Court of Appeals Upheld reinstatement of grants terminated under DEI- and environmental-justice-related executive orders, the first major appellate ruling on the issue

    The Department of Health and Human Services has pursued appeals against several of these rulings, so the restoration list is not static. Institutions should treat any given month’s figures as a snapshot rather than a final count.

    Answer-first: common questions about NIH grant terminations

    How many NIH grants have been terminated?

    Counts vary by source and date because the terminations rolled out over several months. Published figures range from 702 grants in early April 2025 to 2,291 grants worth $2.45 billion in the fullest peer-reviewed accounting, published in PNAS in 2026.

    Have any terminated NIH grants been restored?

    Yes. A federal judge ordered 367 grants restored in June 2025 following the APHA v. NIH ruling, and separate court orders restored NIH and NSF funding to UCLA researchers later that year. In May 2026 the Ninth Circuit Court of Appeals upheld further reinstatements.

    How can a research office check if a specific NIH grant was terminated?

    Research offices should cross-check award numbers against NIH RePORTER, the HHS TAGGS terminated-grants list, and USASpending.gov, then corroborate against the crowdsourced Grant Watch database, which aggregates termination notices submitted directly by affected principal investigators.

    What is the Grant Watch database?

    Grant Watch is an independent tracker built by Harvard T.H. Chan School of Public Health researcher Scott Delaney and computational researcher Noam Ross, combining government data with crowdsourced submissions to document NIH and NSF grant terminations that agency reporting has not consistently disclosed.

    Monitoring exposure: RePORTER, TAGGS, and tracker databases

    For sponsored-programmes offices, the operational question is not just what happened nationally but which of an institution’s own awards are exposed. No single federal system currently gives a real-time, authoritative picture of terminations and restorations together, so offices need to triangulate across sources.

    Tool Custodian Best for
    NIH RePORTER National Institutes of Health Authoritative award status, PI, institution, and funding history lookups
    HHS TAGGS (terminated-grants list) U.S. Department of Health and Human Services Official, periodically updated PDF/CSV of terminated HHS awards by agency
    USASpending.gov U.S. Treasury / OMB Government-wide obligation and de-obligation records across all federal awards
    Grant Watch Independent researcher-run project Early, crowdsourced signal on terminations before official lists update

    A practical monitoring routine for a research office includes:

    1. Reconcile the institution’s active award list against NIH RePORTER monthly, flagging any status changes.
    2. Cross-check flagged awards against the HHS TAGGS terminated-grants file for confirmation of formal termination.
    3. Monitor Grant Watch and institutional legal counsel updates for early warning and litigation status, since court-ordered restorations can lag or precede official RePORTER updates.
    4. Maintain a standing register of affected PIs so restoration notices — which are sometimes issued quietly — are not missed.

    Because restorations have followed litigation rather than routine agency process, research offices that rely solely on award letters risk missing reinstatements that require the institution to formally re-accept funding within a compliance window. Building this monitoring into research administration workflows, rather than treating it as a one-off compliance exercise, is now a standing requirement for institutions with federally funded portfolios.

    Implications for institutions, PIs, and research offices

    The termination-and-restoration cycle has practical consequences beyond the immediate funding gap. Institutions have had to decide whether to bridge-fund affected projects, hold staff and data-collection activities in limbo, or wind down studies that may later be reinstated. Early-career researchers, who held a disproportionate share of terminated training awards, face particular career risk from even temporary funding gaps.

    The pattern of litigation-driven reinstatement also means compliance offices cannot treat a termination notice as final without checking litigation status — a departure from how terminations were historically administered. As appellate rulings such as the May 2026 Ninth Circuit decision accumulate, research offices should expect further reinstatements to arrive on a rolling basis rather than as a single resolution, making ongoing monitoring — not a one-time audit — the operationally necessary posture through the remainder of 2026.

  • NIH Reinstates South Africa Grant Funding: Inside the Subaward Policy Reversal

    The US National Institutes of Health (NIH) has reinstated South Africa grant funding that had been frozen for months, lifting a hold on payments for scores of existing awards after a policy change nearly collapsed one of its largest overseas HIV and tuberculosis research partnerships. The reversal does not undo the underlying policy — a ban on new foreign subawards — but it restores cash flow to active clinical trials and signals how the NIH intends to manage international collaboration going forward.

    For research administrators, sponsored-programs offices, and institutional leaders outside the United States, the episode is a case study in how quickly a funder’s compliance architecture can change, and how little advance notice foreign partners typically get.

    What happened: the subaward ban and its fallout

    On 1 May 2025, the NIH announced it would no longer permit foreign “subawards” — the standard mechanism by which a US-based principal investigator holding a “prime” NIH grant channels a portion of the funds to a collaborating institution abroad. Going forward, foreign partners would instead need to apply for direct awards from the NIH itself.

    The agency framed the change as an effort to improve financial tracking and safeguard national security. In practice, the shift landed on a system that was not ready for it: the NIH’s own staff guidance warned that the infrastructure for processing direct foreign awards might not be operational until 30 September 2025.

    South Africa was disproportionately exposed. The country hosts one of the NIH’s largest overseas research footprints, particularly in HIV and TB clinical trials run through institutions such as the University of the Witwatersrand and the South African Medical Research Council (SAMRC). Disruption had begun even earlier: in March 2025, the NIH moved to freeze or terminate roughly 280 grants tied to South African projects, well before the formal subaward ban took effect.

    The scale of the exposure was significant. In the prior funding year, the NIH had supported approximately 3,600 subawards in foreign countries worth more than $400 million in total. South African institutions alone had been receiving an estimated $100–150 million a year in direct and sub-awarded NIH funding, according to analysis published by Physicians for Human Rights.

    Timeline: from termination to reinstatement

    The sequence of events matters for any institution assessing exposure to future funder policy shifts. The table below sets out the key dates drawn from contemporaneous reporting.

    Date Development
    March 2025 NIH moves to freeze or terminate roughly 280 grants for South African projects
    1 May 2025 NIH formally bans new foreign subawards; requires direct-award applications instead
    27 June 2025 NIH grants official Michelle Bulls confirms existing clinical-research subawards can continue via a new “supplement” mechanism; roughly 100 prime awards to South African researchers permitted to proceed
    30 June 2025 Staff guidance carves out an exception for human-subjects research submitted before the ban
    July 2025 NIH lifts the payment hold on scores of existing South Africa grants, without public explanation
    30 September 2025 (target) NIH’s new direct-award tracking system for foreign partners due to be operational

    Notably, the reinstatement applied to grants that had been frozen, not to the larger population of grants that had been fully terminated. Separately, the NIH has also been under court order to reinstate a portion of the more than 2,000 grants it cancelled nationwide over politically sensitive research topics — a distinct, US-domestic dispute that runs in parallel to the foreign-subaward story.

    Key questions answered

    Have NIH grants been reinstated?

    Yes, partially. In July 2025 the NIH lifted a payment hold on scores of existing South Africa grants and introduced a “supplement” mechanism letting foreign clinical-research subawards continue. It remains unclear whether grants that were fully terminated, rather than merely frozen, will also be restored.

    How many NIH grants have been canceled?

    Across all research areas, the federal government terminated approximately 2,100 NIH grants worth around $9.5 billion, according to tracking by Harvard T.H. Chan School of Public Health. Within that total, roughly 280 South Africa-linked grants were separately frozen or ended starting in March 2025.

    Do South African universities face a funding crisis from the freeze?

    Yes. Institutions including the University of Cape Town and Wits University reported severe financial strain, staff layoffs, and applications for emergency government funding — with the Wits Health Consortium reportedly seeking over R1.8 billion from South Africa’s Treasury to offset the shortfall.

    What it means for foreign subawardees and research offices

    The reversal is narrow, temporary, and administratively burdensome — not a return to the pre-2025 status quo. Institutions that rely on NIH funding through US-based collaborators should treat the following as durable changes rather than transient disruption:

    • Subawards are being phased out for new and renewal applications. The direct-award model is now the NIH’s default path for foreign partners, and institutions should build direct-application capacity rather than assuming subaward continuity.
    • The supplement mechanism is a stopgap, not a policy. An NIH grants official described the conversion process as “a huge administrative lift” — sponsored-programs offices should expect delays and duplicated paperwork during the transition period.
    • Frozen and terminated are legally distinct categories. Institutions holding terminated (not just frozen) awards should not assume the July reinstatement applies to them without written confirmation from their program officer.
    • Compliance offices need contingency plans. Bodies such as NCURA, EARMA, and ARMA have flagged funder-driven subaward volatility as a growing risk category for institutional research administration — not unique to the NIH or to South Africa.

    For research administration teams managing sponsored programmes with US federal funders, the practical lesson is procedural: subaward agreements should now include explicit clauses addressing funder-initiated conversion to direct awards, and institutions should maintain the internal capacity to submit direct NIH applications on short notice.

    What to track going forward

    Three open questions will determine whether this remains a contained South Africa story or a template applied more broadly to NIH’s international grant portfolio.

    First, whether the 30 September 2025 target for a functioning direct-award tracking system holds, or whether the interim supplement mechanism becomes a permanent parallel process. Second, whether the reinstatement logic extends to grants that were fully terminated rather than frozen — a distinction the NIH has not yet resolved publicly. Third, whether other major NIH partner countries in HIV, TB, and global-health research face the same subaward-to-direct-award transition South Africa has already been through.

    For institutions with NIH-funded international partnerships, the prudent posture is to document funder communications carefully, confirm award status (frozen versus terminated) in writing, and monitor NIH policy notices for extensions or modifications to the direct-award transition timeline.